Open AccessA Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
Author(s) -
Dominic Mitchell,
Jason R. Guertin,
Anick Dubois,
MariePierre Dubé,
JeanClaude Tardif,
Ange Christelle Iliza,
Fiorella Fanton-Aita,
Alexis Matteau,
Jacques LeLorier
Publication year - 2018
Publication title -
molecular diagnosis and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.322
H-Index - 42
eISSN - 1179-2000
pISSN - 1177-1062
DOI - 10.1007/s40291-018-0323-2
Subject(s) - statin , medicine , rhabdomyolysis , myopathy , pharmacogenomics , dyslipidemia , physical therapy , intensive care medicine , pharmacology , disease
Statin (HMG-CoA reductase inhibitor) therapy is the mainstay dyslipidemia treatment and reduces the risk of a cardiovascular (CV) event (CVE) by up to 35%. However, adherence to statin therapy is poor. One reason patients discontinue statin therapy is musculoskeletal pain and the associated risk of rhabdomyolysis. Research is ongoing to develop a pharmacogenomics (PGx) test for statin-induced myopathy as an alternative to the current diagnosis method, which relies on creatine kinase levels. The potential economic value of a PGx test for statin-induced myopathy is unknown.